Actively Recruiting
Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-09-22
40
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In patients with Rosai-Dorfman disease (RDD), a treatment regimen of lenalidomide combined with dexamethasone is planned to be used.
CONDITIONS
Official Title
Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Definitively diagnosed adult RDD patients
- Aged between 18 and 80 years
- Treatment-naive or refractory/relapsed
- ECOG performance status score 2
- Judged by clinicians as suitable for treatment with this protocol
- Patients or their families able to understand the study protocol and willing to participate, providing written informed consent
You will not qualify if you...
- Major surgery within 4 weeks before first dose
- Radiotherapy within 4 weeks before first dose
- History of myocardial infarction within the past year
- NYHA Class 3 or 4 congestive heart failure or history of such
- Pregnant or lactating women
- Unable to strictly practice contraception after participation
- Abnormal liver and kidney function: creatinine 176.8 bcmol/L, transaminase and bilirubin levels more than twice normal
- Abnormal blood counts: neutrophils less than 1/L, platelets less than 50/L
- Patients or families unable to understand study conditions and objectives
- Any other condition making patient unsuitable for the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
Actively Recruiting
Research Team
X
Xinxin XX Cao, doctor
CONTACT
H
Huilei HL Miao, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here